The festival posted on their Instagram Story this evening a simple video clip of a phoenix rising from the flames and turning into the Worthy Farm festival’s logo. ‘Glastonbury lineup rumored ...

Janssen Pharmaceutica and MSD Pharmaceutical are also jostling for the shrinking market, as fewer people are eligible for treatment – due to being cured – and the greater number of fast ...

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the ...

Reuters FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to ...

The U.S. and its major trading partners have agreed to reciprocal tariff elimination for pharmaceutical products and chemicals used in drug production for the past 30 years, according to the U.S ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $300.00. The company’s shares closed yesterday at $245.20.

HYDERABAD, India, Feb 26 (Reuters) - Drugmaker Merck (MRK.N), opens new tab, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the ...

Gland Pharma Ltd on Tuesday (February 25) announced that America's drug regulatory watchdog has completed a crucial inspection of its Andhra Pradesh facility. In a regulatory filing, Gland Pharma said ...

Its time for Indian pharma companies to look beyond the U.S. market as the Trump administration has threatened to impose 25% tariff on pharmaceutical imports. This move would disrupt India’s ...

But today, Indian pharma is staring at a far greater challenge — the Trump administration slapping a 25 percent tariff. Even though the finer details of this have not yet emerged ...

Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $68.00. The company’s shares closed last Friday at $67.96.